Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
Moderna (NASDAQ:MRNA) announced the acceptance of five abstracts for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. The presentations include three oral and two poster presentations covering the company's research on propionic acidemia (PA), methylmalonic acidemia (MMA), and Glycogen Storage Disease Type 1a (GSD1a) programs.
The presentations will feature interim data from Phase 1/2 studies of mRNA-3705 for MMA and mRNA-3745 for GSD1a, marking Moderna's first presentations at a scientific congress for these conditions. Additionally, final results from the mRNA-3927 dose-escalation study for PA treatment will be presented, along with clinical burden data and model-informed dose selection analyses.
Moderna (NASDAQ:MRNA) ha annunciato l'accettazione di cinque abstract per la presentazione al 2025 International Congress of Inborn Errors of Metabolism (ICIEM) a Kyoto, Giappone. Le presentazioni includono tre interventi orali e due poster che trattano la ricerca dell'azienda sui programmi per acidemia propionica (PA), acidemia metilmalonica (MMA) e la glicogenosi di tipo 1a (GSD1a).
Gli interventi presenteranno dati intermedi dagli studi di Fase 1/2 su mRNA-3705 per MMA e mRNA-3745 per GSD1a, segnando le prime comunicazioni di Moderna a un congresso scientifico per queste patologie. Inoltre saranno mostrati i risultati finali dello studio di escalation di dose su mRNA-3927 per il trattamento della PA, insieme a dati sull'onere clinico e ad analisi di selezione della dose basate su modelli.
Moderna (NASDAQ:MRNA) anunció la aceptación de cinco resúmenes para su presentación en el 2025 International Congress of Inborn Errors of Metabolism (ICIEM) en Kioto, Japón. Las presentaciones incluyen tres comunicaciones orales y dos pósteres que cubren la investigación de la compañía en los programas de acidemia propiónica (PA), acidemia metilmalónica (MMA) y enfermedad de almacenamiento de glucógeno tipo 1a (GSD1a).
Las presentaciones mostrarán datos interinos de los estudios de Fase 1/2 de mRNA-3705 para MMA y mRNA-3745 para GSD1a, marcando las primeras presentaciones de Moderna en un congreso científico sobre estas afecciones. Además, se presentarán los resultados finales del estudio de escalado de dosis de mRNA-3927 para el tratamiento de PA, junto con datos sobre la carga clínica y análisis de selección de dosis informados por modelos.
Moderna (NASDAQ:MRNA)는 일본 교토에서 열리는 2025 International Congress of Inborn Errors of Metabolism (ICIEM)에 발표할 다섯 건의 초록이 채택되었다고 발표했습니다. 발표는 회사의 프로피온산혈증(PA), 메틸말론산혈증(MMA), 글리코겐 저장병 1a형(GSD1a) 프로그램 연구를 다루는 구두 발표 세 건과 포스터 발표 두 건을 포함합니다.
발표에는 MMA용 mRNA-3705 및 GSD1a용 mRNA-3745의 1/2상 연구 중간 데이터가 포함되며, 이는 해당 질환에 대해 Moderna가 과학 학회에서 처음으로 공개하는 자료입니다. 또한 PA 치료를 위한 mRNA-3927 용량 증량 연구의 최종 결과와 임상 부담 데이터 및 모델 기반 용량 선택 분석도 발표됩니다.
Moderna (NASDAQ:MRNA) a annoncé l'acceptation de cinq résumés pour présentation au 2025 International Congress of Inborn Errors of Metabolism (ICIEM) à Kyoto, Japon. Les présentations comprennent trois communications orales et deux posters portant sur les recherches de la société dans les programmes de acidémie propionique (PA), acidémie méthylmalonique (MMA) et maladie de stockage du glycogène de type 1a (GSD1a).
Les présentations proposeront des données intermédiaires des études de phase 1/2 de mRNA‑3705 pour la MMA et de mRNA‑3745 pour la GSD1a, marquant les premières communications de Moderna dans un congrès scientifique sur ces pathologies. Sont également prévus les résultats finaux de l'étude d'escalade de dose de mRNA‑3927 pour le traitement de la PA, ainsi que des données sur le fardeau clinique et des analyses de sélection de dose informées par modèle.
Moderna (NASDAQ:MRNA) gab bekannt, dass fünf Abstracts zur Präsentation auf dem 2025 International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, angenommen wurden. Die Präsentationen umfassen drei mündliche Vorträge und zwei Poster und behandeln die Forschung des Unternehmens zu den Programmen für Propionsäureämie (PA), Methylmalonsäureämie (MMA) und Glykogenspeicherkrankheit Typ 1a (GSD1a).
Gezeigt werden Zwischendaten aus Phase‑1/2‑Studien zu mRNA‑3705 für MMA und mRNA‑3745 für GSD1a, was die ersten Kongresspräsentationen von Moderna zu diesen Erkrankungen darstellt. Zudem werden die Endergebnisse der Dosiseskalationsstudie zu mRNA‑3927 zur Behandlung von PA sowie Daten zur klinischen Belastung und modellgestützte Analysen zur Dosiswahl vorgestellt.
- None.
- None.
Insights
Moderna's upcoming data presentations on rare metabolic disorders demonstrate diversification beyond COVID vaccines and progress in expanding therapeutic pipeline.
Moderna is broadening its clinical pipeline beyond COVID-19 vaccines with its upcoming presentations at the International Congress of Inborn Errors of Metabolism. The company will present data on three rare metabolic disorder programs: propionic acidemia (PA), methylmalonic acidemia (MMA), and Glycogen Storage Disease Type 1a (GSD1a).
The presentations include interim data from Phase 1/2 studies for both MMA (mRNA-3705) and GSD1a (mRNA-3745) programs—marking the first time Moderna will present data for these indications at a scientific congress. For the PA program, Moderna will present final results from the dose-escalation cohorts of the mRNA-3927-P101 study along with cumulative data from ongoing participants.
These rare metabolic disorders represent significant unmet medical needs with limited treatment options. The company is also presenting model-informed dose selection for a pivotal MMA study, suggesting progression toward later-stage clinical development. This strategic expansion into rare diseases leverages Moderna's mRNA platform technology beyond vaccines into therapeutics.
While these programs are still in early to mid-stage clinical development, their advancement represents important diversification of Moderna's pipeline and potential future revenue streams beyond its established COVID-19 vaccine business. The presentation of these data at a prestigious international congress also provides validation and visibility for these development programs within the scientific and medical communities specialized in metabolic disorders.
CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025 in Kyoto, Japan, at the Kyoto International Conference Center. This includes three oral presentations and two poster presentations across the Company's propionic acidemia (PA), methylmalonic acidemia (MMA) and Glycogen Storage Disease Type 1a (GSD1a) programs. This is the first time Moderna will present data at a scientific congress for MMA and GSD1a.
The details of the presentations are as follows:
Oral Presentation #8 - Organic Acidemias: Clinical Burden of Propionic Acidemia in Japan: A real-world evidence cohort study using a hospital-based healthcare database
Time: Wednesday, September 3, 2025, 2:00 - 4:00 PM JST
Order of Presentation: 1
Location: Room 5
Presenter: Yoko Nakajima
Oral Presentation #8 - Organic Acidemias: mRNA-3705 Therapy for Methylmalonic Acidemia: Interim Data from a Phase 1/2 Study
Time: Wednesday, September 3, 2025, 2:00 - 4:00 PM JST
Order of Presentation: 7
Location: Room 5
Presenter: Sabine Fuchs
Oral Presentation #8 - Organic Acidemias: mRNA-3927 for the Treatment of Propionic Acidemia: Final results from mRNA-3927-P101 Part 1 dose-escalation cohorts and cumulative data from ongoing participants
Time: Wednesday, September 3, 2025, 2:00 - 4:00 PM JST
Order of Presentation: 8
Location: Room 5
Presenter: Andreas Schulze
Poster Presentation #P-521: Model-Informed Dose Selection for the Pivotal Study of mRNA-3705 in Methylmalonic Acidemia
Time: Wednesday, September 3, 2025, 6:00 - 7:00 PM JST
Location: Poster 1 - Annex Hall
Presenter: Min Liang
Poster Presentation #P-246: mRNA-3745 Therapy for GSD1a: Interim reported data from Phase 1/2 Ba1ance Study
Time: Thursday, September 4, 2025, 5:30 - 6:30 PM JST
Location: Poster 1 - Annex Hall
Presenter: Nicola Longo
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
When and where will Moderna present its research at ICIEM 2025?
What types of presentations will Moderna (MRNA) deliver at ICIEM 2025?
Which disease treatments will Moderna showcase at ICIEM 2025?
What is significant about Moderna's MMA and GSD1a presentations at ICIEM 2025?
Which mRNA therapeutics will be discussed in Moderna's ICIEM 2025 presentations?
